EMA/565683/2017 Corr

European Medicines Agency decision

P/0289/2017

of 4 October 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral for phenyl- and piperidin-containing derivative of amiloride (BI 443651) (EMEA-002082-PIP01-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0289/2017

of 4 October 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral for phenyl- and piperidin-containing derivative of amiloride (BI 443651) (EMEA-002082-PIP01-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Boehringer Ingelheim International GmbH on 10 October 2016 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 18 August 2017, in accordance with Article 18 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for phenyl- and piperidin-containing derivative of amiloride (BI 443651), inhalation solution, inhalation use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for phenyl- and piperidin-containing derivative of amiloride (BI 443651), inhalation solution, inhalation use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 - Ingelheim am Rhein, Germany.

EMA/PDCO/297172/2017
London, 18 August 2017

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-002082-PIP01-16

Scope of the application

Active substance(s):

Phenyl- and piperidin-containing derivative of amiloride (BI 443651)

Condition(s):

Treatment of cystic fibrosis

Pharmaceutical form(s):

Inhalation solution

Route(s) of administration:

Inhalation use

Name/corporate name of the PIP applicant:

Boehringer Ingelheim International GmbH

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Boehringer Ingelheim International GmbH submitted for agreement to the European Medicines Agency on 10 October 2016 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 29 November 2016.

Supplementary information was provided by the applicant on 5 May 2017. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition

Treatment of cystic fibrosis

2.1.1. Indication(s) targeted by the PIP

Indicated to improve lung function and reduce pulmonary exacerbations in patients of all age groups with cystic fibrosis in conjunction with standard therapies

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Inhalation solution

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	2	**Study 1** Dose range-finding juvenile toxicity study **Study 2** Definitive juvenile toxicity study
Clinical studies	5	**Study 3** Double-blind, randomised, placebo-controlled, parallel group trial to evaluate pharmacokinetics (PK), pharmacodynamics (PD) and safety of at least 3 doses of BI 443651 as add-on to standard of care in children from 12 to less than 18 years of age (and in adults) with cystic fibrosis **Study 4** Double-blind, randomised, placebo-controlled, parallel group trial to evaluate efficacy and safety of BI 443651 compared to placebo as add-on to standard of care in children from 12 to less than 18 years of age (and in adults) with cystic fibrosis

Area	Number of measures	Description
		Study 5 Double-blind, randomised, placebo-controlled, parallel group trial to evaluate efficacy and safety of BI 443651 compared to placebo as add-on to standard of care in children from 12 to less than 18 years of age (and in adults) with cystic fibrosis **Study 6** Double-blind, randomised, placebo-controlled, parallel group trial to evaluate efficacy and safety of BI 443651 compared to placebo as add-on to standard of care in children from 6 to less than 12 years of age with cystic fibrosis **Study 7** Open label, uncontrolled trial to evaluate PK, PD and safety of BI 443651 in children from birth to less than 6 years of age with cystic fibrosis
Extrapolation, modelling and simulation studies	3	**Study 8** Modelling and simulation study to evaluate the use of BI 443651 for improvement of lung function and reduction in pulmonary exacerbations in children from 12 to less than 18 years of age with cystic fibrosis **Study 9** Dose finding model, including longitudinal dose-response of BI 443651 and dose-exposure-response analyses of trough FEV1 and exacerbation rate **Study 10** Modelling and simulation study to evaluate the use of BI 443651 for improvement of lung function and reduction in pulmonary exacerbations in children from birth to less than 18 years of age with cystic fibrosis
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2025
Deferral for one or more measures contained in the paediatric investigation plan:	Yes